Abstract
3232 Synergistic cytotoxic effects of bortezomib and ck2 inhibitor cx-4945 in acute lymphoblastic leukemia: turning off the prosurvival er chaperone BIP/GRP78 and turning on the proapoptotic NF-κb
Highlights
Acute lymphoblastic leukemia (ALL) is a malignant disorder that originates from hematopoietic precursors committed to either T- or B-cell lineage
We investigated whether casein kinase 2 (CK2) and proteasome inhibition could cause synergistic effects in terms of reduced cell viability in ALL models
Several lines of evidence have recently indicated that CK2 represents a pivotal molecule both regulating hematopoiesis-associated signaling cascades and driving the growth of different blood tumors
Summary
Acute lymphoblastic leukemia (ALL) is a malignant disorder that originates from hematopoietic precursors committed to either T- or B-cell lineage. A bortezomib/CX-4945 combined treatment induces synergistic apoptotic effects in T- and B-ALL cell lines To better understand the molecular determinants of apoptosis induced by such opposing stimuli in ALL cell lines, we studied by western blot analysis the effects of bortezomib/CX-4945 combined treatment on ER stress/UPR markers expression.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
